Kling Bio Announces Collaboration with Sanofi for Accelerated Discovery of Neutralizing Antibodies

Kling Bio Announces Collaboration with Sanofi for Accelerated Discovery of Neutralizing Antibodies

Leverages Kling's technology to discover hard-to-find, immuno-functional antibodies from immortalized human B cellsAccelerating discovery of first-in-class antibodies to transform disease prevention and treatment

Kling Bio announces collaboration with Sanofi

Kling Bio has entered into a collaboration and license option agreement with Sanofi for the discovery of antibodies and epitopes using its B cell immortalisation and screening platform, Kling-Select.

Kling Bio Announces Collaboration with Sanofi for Accelerated Discovery of Neutralizing Antibodies - PressReach

Leverages Kling’s technology to discover hard-to-find, immuno-functional antibodies from immortalized human B cells Accelerating discovery of first-in-class antibodies to transform disease prevention and treatment AMSTERDAM, July 24, 2025 /PRNewswire/ — Kling Bio (“Kling” or “the Company”), a biotech company developing antibody-based drugs for cancer and infectious diseases, today announced it has entered into a collaboration and license option …

Kling Bio and Sanofi link for antibodies and epitopes discovery

Kling Bio has entered a partnership and licence option agreement with Sanofi to discover neutralising antibodies and epitopes.

Kling Bio partners with Sanofi to accelerate antibody discovery

Collaboration aims to advance next-generation therapeutics and vaccines

Kling Bio Announces Collaboration with Sanofi for Accelerated Discovery of Neutralizing Antibodies – Optimum Strategic CommunicationsLink to: Hot topic: Why do medical scandals remain hidden for years?Scroll to top

Leverages Kling’s technology to discover hard-to-find, immuno-functional antibodies from immortalized human B cells Accelerating discovery of first-in-class antibodies to transform disease prevention and treatment Amsterdam, NLD – 24 July 2025 – Kling Bio (“Kling” or “the Company”), a biotech company developing antibody-based drugs for cancer and infectious diseases, today announced it has entered into a […]